AbbVie Inc. company logo

# 1st Gen Model AbbVie Inc. Pharmaceutical preparations

Subscribe >> Deal exit on
Oct. 24, 2017
Deal entry on
Oct. 24, 2017
1.40%Expected margin
67.12% successful of 73 deals
$94.51 Last close price
at 23-oct-2017

ABBV

Model's trade recommendations -3.59% Return for period

8.86% Annual return

$153.19B Market Cap

β 1.51  

ABBV

Model (following trade recommendations)

ABBV

Underlying stock

S&P 500

Index
Return for period -3.59%
11.01%
1.78%
52wk return -2.57%
57.59%
16.82%
52wk Range
55.78—96.48
2000.54—2399.63
Sortino ratio 1.09
Sharpe ratio 0.79
Norm. RMSE 0.56%
Downside risk 8.05%
Volatility 11.14%
  • 2.56 (2.66%) Div (Yield)
  • BUY Analysts consensus recommendation

AbbVie is a global, research-based biopharmaceutical company. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie aims to help patients' live healthier lives and collaborate on sustainable healthcare solutions.

Industry sector: Medical

Sector classification: Pharmaceutical preparations

Deep Learning based analysis and prediction model for AbbVie Inc. (ABBV) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.

Model is in the production pipeline since April 29, 2015.

Market data for ABBV model training are being downloaded from the Quandl premium datasets on a daily basis.

Model is being retrained on a daily basis.

Float 1590M
P/E 18.81
Shares Outstanding 1594M
% Held by Insiders 0.23%
% Held by Institutions 68.43%
EPS (last reported FY) $4.82
EPS (last reported Q) $1.42
EPS, estimated (last reported Q) $1.40
Total revenues $26 B
Net income $6 B